financetom
Business
financetom
/
Business
/
Polyrizon (PLRZ) Stock Skyrocketed Over 240% Today: What's Going On?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Polyrizon (PLRZ) Stock Skyrocketed Over 240% Today: What's Going On?
May 26, 2025 12:30 AM

Shares of Polyrizon Ltd ( PLRZ ) surged 223% to 82 cents Friday afternoon, following a reversal in reverse stock split plans from Thursday.

What To Know: On Thursday morning, the company had announced a 1-for-10 reverse stock split, intended to consolidate every ten shares into one, with trading on a post-split basis to begin May 5. The move originally aimed to bolster the company's per-share price, a common tactic to meet minimum listing requirements.

However, late Thursday, Polyrizon ( PLRZ ) canceled the reverse split, stating it would not proceed with the plan as previously disclosed.

The change has triggered a flurry of speculative trading during Friday’s session, as the company provided no further explanation for the decision, leaving investors to interpret the implications.

Friday’s volatility also highlights the sensitivity of small-cap stocks to corporate actions and the potential impact of sudden governance shifts.

Read Also: Apple Stock Falls After Cook Warns of $900M Tariff Impact

How To Buy PLRZ Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Polyrizon’s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

According to data from Benzinga Pro, PLRZ has a 52-week high of $4.80 and a 52-week low of $0.25.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Chemed Insider Sold Shares Worth $816,255, According to a Recent SEC Filing
Chemed Insider Sold Shares Worth $816,255, According to a Recent SEC Filing
Jun 7, 2024
03:16 PM EDT, 06/07/2024 (MT Newswires) -- Kevin J McNamara, Director, President and CEO, on June 06, 2024, sold 1,500 shares in Chemed ( CHE ) for $816,255. Following the Form 4 filing with the SEC, McNamara has control over a total of 107,049 shares of the company, with 107,049 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/19584/000095017024070509/xslF345X03/ownership.xml Price: 544.96, Change: +0.79,...
Copper output from Chile's Codelco down 6% in April
Copper output from Chile's Codelco down 6% in April
Jun 7, 2024
SANTIAGO, June 7 (Reuters) - Copper production from Chile's state-run miner Codelco, the world's largest producer of the metal, dropped 6.1% in April compared to the same month last year to total 95,100 metric tons, data from copper commission Cochilco showed on Friday. Copper output also fell during the month at Chile's Escondida mine, though it edged up 1.9% in...
Pfizer's Paxlovid fails as 15-day treatment for long COVID, study finds
Pfizer's Paxlovid fails as 15-day treatment for long COVID, study finds
Jun 7, 2024
(Reuters) - A 15-day course of Pfizer's ( PFE ) COVID-19 antiviral treatment Paxlovid did not relieve symptoms of long COVID, according a study by Stanford University researchers. Currently, there are no proven treatments specifically for long COVID in which a host of symptoms can last for many months after initial coronavirus infection. Scientists and patients had hoped that Pfizer's...
Arcturus Therapeutics Prospective Cystic Fibrosis Treatment Shows Positive Results -- Shares Tumble
Arcturus Therapeutics Prospective Cystic Fibrosis Treatment Shows Positive Results -- Shares Tumble
Jun 7, 2024
03:16 PM EDT, 06/07/2024 (MT Newswires) -- Arcturus Therapeutics ( ARCT ) slumped more than 29% in Friday trading, despite reporting positive preliminary data from phase 1 and phase 1b study of its ARCT-032 prospective treatment for cystic fibrosis. Appearing at an industry conference in Glasgow, Scotland, executives of the the messenger RNA medicines and vaccines company said the inhaled...
Copyright 2023-2026 - www.financetom.com All Rights Reserved